No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Shuttle Pharmaceuticals Holdings, Inc. (SHPH) stock was $4.06 as of Oct 6, 2026, 4:00 PM EDT, up 1.25% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -91.0% · 3-year avg -84.2%/yr
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.
Drug Manufacturers - Specialty & Generic · Gaithersburg, MD
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-3.84
vs Estimate
N/A
Revenue
$0.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1SHPH | $2.38M | $4.06 | +1.25% | -90.95% | N/A | N/A | N/A |
| 2MBRX | $2.38M | $0.45 | -6.53% | -95.81% | -78.48% | -64.00% | vs SHPH |
| 3ONCO | $2.37M | $0.66 | -1.77% | -99.55% | N/A | N/A | vs SHPH |
| 4FBLG | $2.37M | $1.13 | -4.24% | -89.14% | N/A | N/A | vs SHPH |
| 5CELZ | $2.32M | $0.90 | -2.13% | -71.43% | -57.96% | -72.19% | vs SHPH |
| 6JAGX | $2.44M | $5.62 | +18.82% | N/A | N/A | N/A | vs SHPH |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$4.06
High
N/A
